1. Pink Sheet
  2. >>Legislation
  3. >>Elections

US FDA Hiring: Growth Continued During The Quarter That Included Presidential Election

 
• By Derrick Gingery

CDER and CBER once again posted net employee gains, even during the quarter that included the presidential election, despite fears that many would leave rather than endure the changes to be imposed by President Trump.

An exodus of FDA employees did not appear to have materialized at the end of 2024. (Shutterstock)
Key Takeaways
  • The CDER net increase of 14 employees in Q1 of FY 2025 was its smallest since FY 2023, while the CBER net of 47 was its largest.
  • The data suggest an exodus of employees had not started in the weeks after President Trump’s election.
  • But more could leave once President Trump fully implements his policies.

An exodus of US Food and Drug Administration employees following the election of Donald Trump as president was not apparent after the first quarter of fiscal year 2025, at least...

Both centers reported net gains in employee count once again during the fiscal quarter that ended 31 December 2024. CDER boasted 6,058 employees on 1 January 2025, up from 6,044...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Elections

US Tariff Impact On Korea Dissected As Country Gears For Presidential Election

 
• By Jung Won Shin

Analysts expect a limited impact on South Korean pharma from US tariffs, even if imposed at a later date. Meanwhile, the early June domestic presidential election is set to determine the direction of policies in the sector.

‘A Lot Of That, It’s Meant To Start A Conversation’: How To Work With Trump

 
• By Alaric DeArment and Jessica Merrill

Biotech execs and lobbyists try to explain the Trump Administration's policy strategy and how to thrive in it.

Bracing For RFK At HHS: Vaccine Safety Commission Likely First Step

 
• By Michael McCaughan

Robert F. Kennedy Jr. will become HHS secretary while retaining his anti-vaccine positions. His first action likely will be creating a new safety commission, which industry must hope holds off more drastic action.

Trump And Tariffs Top Generic Industry Concerns

 
• By Dave Wallace

At a lively AAM Access! conference in Florida, AAM President and CEO John Murphy acknowledged the negative effects of potential tariffs, but also suggested that the second Trump Administration could be an opportunity for the generics and biosimilars sectors to advance market reforms.

More from Legislation

EU HTA Regulation: How Rare Disease Drug Makers Can Meet Worrisome JCAs Data Requirements

 
• By Francesca Bruce

In an interview with the Pink Sheet, Fonadazione Telethon’s Stefano Benvenuti discusses how companies developing and marketing rare disease treatments can overcome the challenges presented by EU-joint clinical assessment evidence requirements.

House Budget Bill Includes Delayed Orphan Fix, Also Risks Downstream Cell and Gene Coverage

 
• By Sarah Karlin-Smith

The first two classes of negotiated drugs under the Inflation Reduction Act would not benefit from a rare disease adjustment House Republicans included in their reconciliation package.

Trump’s Rx Pricing Order: The Best-Case And Worst-Case Scenarios

 
• By Derrick Gingery

US trade and tariff leverage might successfully push European and other countries to pay more for medicines, but if not, President Trump’s executive order includes potential US drug withdrawal and other options to entice industry to lower US prices.